Provided by Tiger Trade Technology Pte. Ltd.

Cabaletta Bio

3.13
-0.0600-1.88%
Post-market: 3.180.0500+1.60%19:30 EDT
Volume:4.40M
Turnover:14.19M
Market Cap:532.10M
PE:-2.03
High:3.34
Open:3.20
Low:3.09
Close:3.19
52wk High:4.23
52wk Low:1.40
Shares:170.00M
Float Shares:141.48M
Volume Ratio:0.66
T/O Rate:3.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5420
EPS(LYR):-2.1000
ROE:-93.20%
ROA:-48.19%
PB:2.53
PE(LYR):-1.49

Loading ...

Cabaletta Bio is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Aug 14

Cabaletta Bio (CABA) Gets a Buy from Cantor Fitzgerald

TIPRANKS
·
Aug 14

Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS), Cabaletta Bio (CABA) and Capricor Therapeutics (CAPR)

TIPRANKS
·
Aug 14

Wells Fargo Sticks to Their Hold Rating for Cabaletta Bio (CABA)

TIPRANKS
·
Aug 14

U.S. Research Roundup-Cisco, Fox Corp, Target

Reuters
·
Aug 14

Cabaletta Bio, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Ovid Therapeutics Q2 Revenue Beats Estimates

Reuters
·
Aug 13

Cabaletta Bio Posts Corporate Presentation on Rese-Cel CD19 CAR-T Program for Autoimmune Diseases

Reuters
·
Aug 13

Cabaletta Bio Q2 EPS $(0.34) Beats $(0.39) Estimate

Benzinga Earnings
·
Aug 13

Cabaletta Bio Q2 EPS USD -0.34

THOMSON REUTERS
·
Aug 13

Cabaletta Bio Q2 FY26 Net Loss Narrows 11.69% to $51.02 Million; R&D Expenses Rise 18.06% to $44.43 Million

Reuters
·
Aug 13

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire
·
Aug 13

Cabaletta Bio, Inc. Expected to Post a Loss of 37 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Cabaletta Bio Inc Expected to Post a Loss of 37 Cents a Share - Earnings Preview

Reuters
·
Aug 03

Cabaletta Bio Hits Reset on RESET-MS Trial, Narrowing Near-Term Upside in Multiple Sclerosis

TIPRANKS
·
Jun 26

Cabaletta Bio shareholders approve increase in authorized common shares to 600 million

Reuters
·
Jun 11

Analysts Offer Insights on Healthcare Companies: Cabaletta Bio (CABA) and Tenaya Therapeutics (TNYA)

TIPRANKS
·
Jun 04

Cabaletta Bio: Buy Rating Reiterated as Rese-cel Data Strengthen Outpatient Cell Therapy Thesis; $16 Price Target Maintained

TIPRANKS
·
Jun 04

Cabaletta Bio presents new data for rese-cel in autoimmune diseases

TIPRANKS
·
Jun 03

Cabaletta Bio Highlights Rese-cel Data and Pivotal Path

TIPRANKS
·
Jun 03